Twitter

Chordate initiates market introduction of the migraine indication in Saudi Arabia

The first demonstration with Ozilia® Migraine was conducted yesterday at King Abdulaziz Medical City, a National Guard hospital in Jeddah. The company’s distributor, Janin Medical, has been preparing for the launch since this spring – and this marks the first step after receiving market approval from the SFDA (Saudi Food and Drug Authority) a week ago.

Ozilia demonstration at King Abdulaziz Medical City
Mohamad Ibrahim, sales manager, Janin Medical, during Ozilia-demonstration at King Abdulaziz Medical City.

King Abdulaziz Medical City, with 751 beds, is a significant part of the Ministry of National Guard Health Affairs’ approximately 3,000+ beds across the kingdom, responsible for the healthcare of National Guard personnel and their families. Out of the country’s nearly 500 hospitals, about 335 are publicly owned or belong to various defense ministries, with the remainder being privately operated. The demonstration was carried out at the department of Dr. Abdullah Attar, head of neuroscience, by Janin’s sales manager Mohamad Ibrahim and Chordate’s General Manager Alain Durante, based in Jeddah.

“It’s a great feeling to finally get started after a period of preparation for the migraine introduction, and that we managed to secure product registration faster than expected,” says Alain Durante, Chordate General Manager, MEA area.

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia®, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter